Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)

Starting soon

Conditions studied: Prostate Cancer, Active Surveillance for Prostate Cancer

In brief

The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.

Key facts

Study ID

NCT07478536

Run by

Insel Gruppe AG, University Hospital Bern

People needed

350

Starts

2026-07-01

Expected to finish

2028-08-31

Last updated by the study team

2026-06-22

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adult Men ≥ 18 y. o.
• Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS)
• First inclusion in Active Surveillance (AS) after 1st January 2022.
• Scheduled for follow-up with systematic and/or Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available

You may not qualify if…

• - Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy).
• Patient with intermediate- or high-risk prostate cancer
• Urinary catheterization within the past 6-8 weeks
• Contraindications to Magnetic Resonance Imaging (MRI) or biopsy

Where it is running

• Inselspital, University Hospital of Bern — Bern, Canton of Bern, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.